Novo Nordisk A/S
(NYSE : NVO)

( )
NVO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. -0.43%93.652.3%$1015.98m
MRKMerck & Co., Inc. -0.22%82.470.7%$998.22m
JNJJohnson & Johnson -0.67%149.130.7%$986.09m
PFEPfizer Inc. -0.55%36.310.9%$935.39m
BMYBristol-Myers Squibb Co. -0.45%66.081.0%$855.55m
LLYEli Lilly & Co. -0.10%140.981.1%$484.80m
NVSNovartis AG -0.43%97.210.2%$212.23m
GSKGlaxoSmithKline Plc -0.43%43.550.2%$168.29m
AZNAstraZeneca Plc 2.76%49.171.2%$142.61m
RETAReata Pharmaceuticals, Inc. 1.10%228.143.5%$96.68m
NVONovo Nordisk A/S 1.02%64.100.1%$83.39m
GNPXGenprex, Inc. 14.49%4.900.0%$82.51m
SNYSanofi 2.42%51.140.2%$82.48m
BHCBausch Health Cos., Inc. 1.21%28.080.0%$80.83m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.41%46.420.0%$61.69m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.